IEV407 alone or with hormone therapy for advanced HR+/HER2- breast cancer
Tests IEV407, alone or with fulvestrant or letrozole, in adults with advanced breast cancer.
Plain-language title generated from the registry record
Registry title: Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
Key facts
- Where
- Seoul, South KoreaSee the site
- Phase
- Phase 1
Where in South Korea
- SeoulSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT07604571
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients with advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-negative) breast cancer.Read full original descriptionShow less
An Open-label, Multi-center, Phase I/Ib Study of IEV407 as a Single Agent and in Combination With Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2- Negative Breast Cancer
The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients with advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-negative) breast cancer.
Inclusion: Age ≥ 18 years old; Patients with one of the following indications:; Dose escalation (IEV407 single agent and in combination with fulvestrant or letrozole):; HR+/HER2- aBC with disease progression on or following, or have been intolerant to, at least one line of endocrine-based therapy in combination with a CDK4/6 inhibitor and at least one additional line of systemic therapy in the unresectable/metastatic setting and not be a candidate for any available standard therapy, in the investigator's judgement; Dose expansion of IEV407 in combination with fulvestrant: HR+/HER2- aBC with disease progression on or following, or have been intolerant to, endocrine-based therapy in combination with a CDK4/6 inhibitor. They must not have received more than two prior lines of endocrine-based therapy in the unresectable/metastatic setting. Prior cytotoxic chemotherapy and/or antibody-drug conjugate therapies in the unresectable/metastatic setting are not allowed.
Exclusion: Concurrent use of hormone replacement therapy; Impaired cardiac function or clinically significant cardiac disease; For the combination treatment of IEV407 with fulvestrant or letrozole: Patients with symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine-based therapy; Other protocol-defined inclusion/exclusion criteria may apply; Patients with inadequate bone marrow and/or organ functions with out-of-range laboratory values; Women of childbearing potential who are unwilling to use highly effective contraception methods, pregnant or nursing women.